Evidence map›Paper›PMID 28049491›Full record

Trial reportTrials2017

Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial.

Sophie E Rowbotham, Doug Cavaye, Rene Jaeggi, Jason S Jenkins, Corey S Moran, Joseph V Moxon, Jenna L Pinchbeck, Frank Quigley, Christopher M Reid, Jonathan Golledge

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Development of pharmacotherapies for abdominal aortic aneurysms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  4. Article
  5. Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm.American journal of physiology. Heart and circulatory physiology · 2020
    Review
  6. Article
  7. Pharmacologic Management of Aneurysms.Circulation research · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Sophie E RowbothamThe University of Queensland, School of Medicine, Herston, QLD, 4006, Australia.
Doug CavayeDepartment of Vascular Surgery. Holy Spirit Northside Private Hospital, Chermside, QLD, 4032, Australia.
Rene JaeggiQueensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD, 4811, Australia.
Jason S JenkinsDepartment of Vascular Surgery, The Royal Brisbane and Women's Hospital, Herston, QLD, 4029, Australia.
Corey S MoranQueensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD, 4811, Australia.
Joseph V MoxonQueensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD, 4811, Australia.
Jenna L PinchbeckQueensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD, 4811, Australia.
Frank QuigleyMater Medical Centre, Pimlico, QLD, 4812, Australia.
Christopher M ReidSchool of Public Health, Curtin University, Perth, WA, 6000, Australia.
Jonathan GolledgeQueensland Research Centre for Peripheral Vascular Disease, James Cook University, Townsville, QLD, 4811, Australia. jonathan.golledge@jcu.edu.au.ORCID 0000-0002-5779-8848
James Cook University · AUCurtin University · AUHoly Spirit Northside Private Hospital · AUMater Health Services · AURoyal Brisbane and Women's Hospital · AUThe University of Queensland · AUTownsville Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbdominal aortic aneurysm (AAA) is a slowly progressive destructive process of the main abdominal artery. Experimental studies indicate that fibrates exert beneficial effects on AAAs by mechanisms involving both serum lipid modification and favourable changes to the AAA wall. METHODS/

designFenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre, randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair. A total of 42 participants scheduled for an elective open AAA repair will be randomly assigned to either 145 mg of fenofibrate per day or identical placebo for a minimum period of 2 weeks prior to surgery. Primary outcome measures will be macrophage number and osteopontin (OPN) concentration within the AAA wall as well as serum concentrations of OPN. Secondary outcome measures will include levels of matrix metalloproteinases and proinflammatory cytokines within the AAA wall, periaortic fat and intramural thrombus and circulating concentrations of AAA biomarkers. DISCUSSION: At present, there is no recognised medical therapy to limit AAA progression. The FAME trial aims to assess the ability of fenofibrate to alter tissue markers of AAA pathology.

trial registrationAustralian New Zealand Clinical Trials Registry, ACTRN12612001226897 . Registered on 20 November 2012.

Indexed as

Administration, OralAortic Aneurysm, AbdominalBiomarkersClinical ProtocolsCytokinesDouble-Blind MethodFenofibrateHumansHypolipidemic AgentsMacrophagesMatrix MetalloproteinasesOsteopontinQueenslandResearch DesignTime FactorsTreatment OutcomeBiomarkersCytokinesFenofibrateHypolipidemic AgentsMatrix MetalloproteinasesOsteopontinSPP1 protein, humanAbdominal aortic aneurysmClinical trialFenofibrateMacrophageOsteopontin

Identifiers

PMID28049491
PMCPMC5209849
OpenAlexW2562942821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.